DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Phase IIIB Subcutaneous Missed Dose Study

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: Placebo

First Posted Date: 2007-09-24

Last Posted Date: 2015-04-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 270

Registration Number: NCT00533897

Locations: 🇺🇸
Mountain State Clinical Research, Clarksburg, West Virginia, United States
🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸
New England Research Associates, Llc, Trumbull, Connecticut, United States

and more 11 locations

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Phase 2

Terminated

Conditions: Psoriatic Arthritis

Interventions: Drug: Placebo
Drug: Abatacept

First Posted Date: 2007-09-24

Last Posted Date: 2012-08-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 191

Registration Number: NCT00534313

Locations: 🇺🇸
Desert Medical Advances, Palm Desert, California, United States
🇺🇸
Arthritis Clinic & Carolina Bone & Joint, Pa, Charlotte, North Carolina, United States
🇺🇸
Boling Clinical Trials, Upland, California, United States

and more 17 locations

Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2007-09-14

Last Posted Date: 2023-05-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 121

Registration Number: NCT00529763

Locations: 🇨🇳
Local Institution - 0004, Fuzhou, Fujian, China
🇨🇳
Local Institution - 0008, Suzhou, Jiangsu, China
🇨🇳
Local Institution, Hangzhou, Zhejiang, China

and more 1 locations

Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease

Phase 4

Completed

Conditions: Hypercholesterolemia

First Posted Date: 2007-09-14

Last Posted Date: 2011-04-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 232

Registration Number: NCT00529178

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Phase 2

Completed

Conditions: Lung Cancer
Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Ipilimumab
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2007-09-11

Last Posted Date: 2018-07-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 334

Registration Number: NCT00527735

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States
🇺🇦
Local Institution, Uzhgorod, Ukraine

and more 22 locations

DDI HV (ATV - Merck)

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Atazanavir + Raltegravir
Drug: Raltegravir
Drug: Atazanavir

First Posted Date: 2007-08-20

Last Posted Date: 2010-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT00518297

Locations: 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States

Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: BMS-690514

First Posted Date: 2007-08-15

Last Posted Date: 2008-10-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9

Registration Number: NCT00516451

Locations: 🇯🇵
Local Institution, Chuo-Ku, Tokyo, Japan

A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: tanespimycin
Drug: Bortezomib

First Posted Date: 2007-08-09

Last Posted Date: 2015-12-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT00514371

Locations: 🇺🇸
Local Institution, Columbia, South Carolina, United States

A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

Phase 4

Terminated

Conditions: Schizophrenia
Metabolic Syndrome

Interventions: Drug: Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
Drug: Aripiprazole

First Posted Date: 2007-07-27

Last Posted Date: 2013-12-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 125

Registration Number: NCT00508157

Locations: 🇹🇷
Local Institution, Izmir, Turkey

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: BMS-686117
Drug: Byetta
Drug: Placebo

First Posted Date: 2007-07-27

Last Posted Date: 2009-03-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT00508287

Locations: 🇺🇸
Elite Research Institute, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
New Orleans Center For Clinical Research, Knoxville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy